. 2010 Jan 19;12(5):374–379. doi: 10.1111/j.1751-7176.2009.00259.x

Table II.

Quantitative Changes of MS Criteria and Different Biochemical Parameters According to the Presence of MS

N=642		MS (n=171; 26.7%)	No MS (n=471; 73.3%)	P ^MS	P ^{No MS}	P ^{MS vs No MS}
Body mass index, kg/m²	Baseline	28.9±3.9	26.2±2.9	NS	NS	<.001
Body mass index, kg/m²	Study end	28.8±3.8	26.3±3.0	NS	NS	<.001
Waist circumference, cm	Baseline	100.8±9.3	95.3±8.7	NS	NS	.006
Waist circumference, cm	Study end	99.4±9.3	95.4±9.1	NS	NS	.006
Systolic blood pressure, mm Hg	Baseline	138.6±17.6	124.4±18.4	<.001	NS	<.001
Systolic blood pressure, mm Hg	Study end	129.9±17.6	124.7±18.9	<.001	NS	<.001
Diastolic blood pressure, mm Hg	Baseline	86.4±9.5	80.3±11.5	NS	NS	<.001
Diastolic blood pressure, mm Hg	Study end	82.8±10.1	79.5±11.0	NS	NS	<.001
Pulse pressure, mm Hg	Baseline	52.2±6.3	44.1±5.1	.01	NS	<.001
Pulse pressure, mm Hg	Study end	47.1±5.2	45.2±5.3	.01	NS	<.001
Total cholesterol, mg/dL	Baseline	187.4±40.1	182.8±42.0	<.001	<.001	NS
Total cholesterol, mg/dL	Study end	167.7±34.6	166.7±30.8	<.001	<.001	NS
LDL cholesterol, mg/dL	Baseline	119.4±35.5	116.0±35.6	<.001	<.001	NS
LDL cholesterol, mg/dL	Study end	99.5±25.1	99.1±25.5	<.001	<.001	NS
NEFA, mg/dL	Baseline	213.8±69.3	148.1±50.4	NS	NS	<.001
NEFA, mg/dL	Study end	201.6±93.3	152.5±57.0	NS	NS	<.001
HDL cholesterol, mg/dL	Baseline	35.6±8.7	43.7±12	<.001	<.001	<.001
HDL cholesterol, mg/dL	Study end	38.5±9.4	45.3±12.2	<.001	<.001	<.001
VLDL cholesterol, mg/dL	Baseline	32.7±26.8	22.6±19.9	<.001	<.001	<.001
VLDL cholesterol, mg/dL	Study end	27.7±18.7	21.4±11.4	<.001	<.001	<.001
Triglycerides, mg/dL	Baseline	176.8±90.9	111.9±46.1	<.001	NS	<.001
Triglycerides, mg/dL	Study end	149.9±73.2	107.7±44.6	<.001	NS	<.001
Apolipoprotein B, mg/dL	Baseline	107.4±26.6	93.7±26.2	<.001	<.001	<.001
Apolipoprotein B, mg/dL	Study end	97.0±27.1	87.0±29.9	<.001	<.001	<.001
TG/HDL cholesterol	Baseline	5.3±3.5	2.8±1.6	<.001	NS	<.001
TG/HDL cholesterol	Study end	4.3±3.2	2.6±1.6	<.001	NS	<.001
Fasting glucose, mg/dL	Baseline	125.6±37.0	102.9±22.6	<.001	NS	<.001
Fasting glucose, mg/dL	Study end	120.1±42.2	103.2±19.5	<.001	NS	<.001
HbA_1c, %	Baseline	7.7±2.4	5.6±0.3	NS	NS	.025
HbA_1c, %	Study end	7.7±2.7	5.6±0.4	NS	NS	.025
HOMA index	Baseline	4.9±2.9	2.9±1.9	.05	NS	.059
HOMA index	Study end	3.9±3.1	3.1±2.8	.05	NS	.059

Abbreviations: HbA_1c, glycated hemoglobin A_1c; HDL, high‐density lipoprotein; HOMA, homeostasis model assessment; LDL, low‐density lipoprotein; MS, metabolic syndrome; NEFA, nonesterified fatty acid; NS, not significant; P ^MS, P value between baseline and study end in patients with MS; P ^{MS vs No MS}, P value between baseline values in patients with and without MS; P ^{No MS}, P value between baseline and study end in patients without MS; TG, triglycerides; VLDL, very low‐density lipoprotein.